Want to see JP:141A full AI Analyst Report?
Top Page
Trial Holdings Inc.
(141A)
Select Model
Select Model
Rating:53Neutral
Price Target:
¥3,735.00
▲(20.48% Upside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by elevated balance-sheet risk (sharp leverage increase) and weakened net profitability/ROE, despite strong revenue growth and improved cash generation. Technicals are supportive with strong momentum, but overbought signals add near-term risk, and valuation remains stretched given the high P/E and modest dividend yield.
Positive Factors
Accelerating Revenue Growth
Revenue growth has been strong and generally accelerating, with a sharp step-up in 2026. This indicates expanding sales scale and can improve operating leverage over time, although conversion into bottom-line profit remains important for durability.
Negative Factors
Sharp Leverage Increase
The sharp rise in debt relative to equity increases financial risk and reduces flexibility. Higher leverage can constrain investment, raise sensitivity to operating weakness, and make future earnings more vulnerable to financing costs or balance-sheet stress.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Revenue growth has been strong and generally accelerating, with a sharp step-up in 2026. This indicates expanding sales scale and can improve operating leverage over time, although conversion into bottom-line profit remains important for durability.
Read all positive factors
Trial Holdings Inc. (141A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥465.60B
Dividend Yield0.45%
Average Volume (3M)1.03M
Price to Earnings (P/E)131.8
Beta (1Y)0.42
Revenue Growth69.13%
EPS Growth-70.11%
CountryJP
Employees7,080
SectorConsumer Defensive
Sector Strength42
IndustryDiscount Stores
Share Statistics
EPS (TTM)76.01
Shares Outstanding122,848,400
10 Day Avg. Volume1,438,280
30 Day Avg. Volume1,025,323
Financial Highlights & Ratios
PEG Ratio-1.48
Price to Book (P/B)2.80
Price to Sales (P/S)0.27
P/FCF Ratio7.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.58
Revenue Forecast (FY)¥1.44T
Trial Holdings Inc. Business Overview & Revenue Model
Company Description
Trial Holdings Inc. is a diversified enterprise actively engaged across several key sectors, including retail commerce, supply chain management, financial technology services, and specialized retail technology solutions. The company manages an ext...
How the Company Makes Money
null...
Trial Holdings Inc. Financial Statement Overview
Summary
Income Statement
60
Neutral
Balance Sheet
35
Negative
Cash Flow
58
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.22T | 1.36T | 806.59B | 720.44B | 655.48B | 597.69B |
| Gross Profit | 294.99B | 337.38B | 155.13B | 134.00B | 117.53B | 103.49B |
| EBITDA | 62.76B | 69.13B | 33.73B | 30.78B | 25.03B | 21.58B |
| Net Income | 9.30B | 3.52B | 11.75B | 11.44B | 8.09B | 7.13B |
Balance Sheet | ||||||
| Total Assets | 784.94B | 807.82B | 300.28B | 283.63B | 200.64B | 185.73B |
| Cash, Cash Equivalents and Short-Term Investments | 60.47B | 68.90B | 72.33B | 91.95B | 23.90B | 27.43B |
| Total Debt | 392.13B | 394.63B | 38.56B | 16.16B | 19.61B | 24.44B |
| Total Liabilities | 650.77B | 673.45B | 171.25B | 165.44B | 132.62B | 126.02B |
| Stockholders Equity | 130.87B | 130.90B | 126.13B | 115.68B | 65.89B | 57.96B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 47.10B | -38.41B | 36.90B | 2.55B | 10.01B |
| Operating Cash Flow | 0.00 | 92.06B | -4.45B | 59.50B | 18.45B | 22.34B |
| Investing Cash Flow | 0.00 | -405.01B | -35.89B | -26.00B | -16.77B | -13.49B |
| Financing Cash Flow | 0.00 | 309.39B | 20.77B | 34.50B | -5.19B | -4.32B |
Trial Holdings Inc. Technical Analysis
Positive
3100.00
Price Trends
3028.90
Positive
3450.01
Positive
3219.10
Positive
Market Momentum
144.50
Negative
77.03
Negative
75.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:141A, the sentiment is Positive. The current price of 3100 is below the 20-day moving average (MA) of 3199.45, above the 50-day MA of 3028.90, and below the 200-day MA of 3219.10, indicating a bullish trend. The MACD of 144.50 indicates Negative momentum. The RSI at 77.03 is Negative, neither overbought nor oversold. The STOCH value of 75.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:141A.
Trial Holdings Inc. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ¥346.13B | 9.03 | 9.80% | 2.01% | -0.35% | 209.70% | |
71 Outperform | ¥103.42B | 10.50 | ― | 2.59% | 0.95% | 3.40% | |
67 Neutral | ¥223.65B | 17.51 | ― | 2.62% | 3.25% | 1.50% | |
65 Neutral | ¥136.47B | 11.13 | ― | 1.90% | 7.40% | -1.99% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥2.85T | 25.19 | 16.92% | 0.99% | 8.84% | 21.51% | |
53 Neutral | ¥465.60B | 131.78 | ― | 0.56% | 69.13% | -70.11% |
* Consumer Defensive Sector Average
JP:141A
Trial Holdings Inc.
3,795.00
1,355.30
55.55%
JP:7532
Pan Pacific International Holdings
915.50
-139.62
-13.23%
JP:8242
H2O Retailing Corporation
2,869.00
772.07
36.82%
JP:8194
Life Corporation
2,613.00
162.98
6.65%
JP:8198
Maxvalu Tokai Co., Ltd.
3,240.00
72.76
2.30%
JP:9974
BELC Co., Ltd.
6,600.00
-680.86
-9.35%
Trial Holdings Inc. Corporate Events
Trial Holdings Updates FY2026 Results and Issues FY2027 Forecast
Aug 13, 2026
Trial Holdings, Inc. has released materials outlining its financial results for the fiscal year ending June 30, 2026, covering the period from July 1, 2025, to June 30, 2026. The release also notes partial modifications to previously reported figu...
TRIAL Holdings Posts Surging Sales but Profit Drops as Balance Sheet Swells
Aug 13, 2026
TRIAL Holdings reported a sharp 67.6% jump in net sales to ¥1.35 trillion and a doubling of EBITDA for the fiscal year ended June 30, 2026, driven by business expansion, though operating margin remained modest and profit attributable to owner...
TRIAL Holdings Tops FY2026 Forecasts and Lifts Year-End Dividend
Aug 13, 2026
TRIAL Holdings reported full-year results for the fiscal year ended June 30, 2026 that modestly beat its May forecast on sales and more strongly on profits, helped by stronger-than-expected net sales and gross profit and lower extraordinary losses...
TRIAL Holdings Posts Strong July Sales as TRIAL–SEIYU Integration Gains Traction
Aug 10, 2026
TRIAL Holdings reported continued sales momentum in July, with same-store sales at TRIAL outlets rising 4% year on year and SEIYU stores posting an 8.9% gain, supported by strong demand for fresh foods, private-brand items and summer-related produ...
TRIAL Holdings Beats FY2026 Sales Target as Anniversary Campaign and Store Expansion Drive Growth
Jul 10, 2026
TRIAL Holdings reported solid same-store sales performance for FY6/2026, with SSS up 2.1% year-on-year, exceeding its full-year target despite unfavorable weather and fewer holidays. A Grand Anniversary Sale marking one year since the integration ...
Trial Holdings Secures ¥367.4bn Syndicated Loan to Refinance Seiyu Acquisition Debt
Jun 23, 2026
Trial Holdings has arranged a large syndicated term loan, led by MUFG Bank and joined by domestic financial institutions, to refinance a one-year bridge loan used to acquire Seiyu. The new unsecured facility totals 367.4 billion yen across two tra...
TRIAL Holdings Posts Robust May Sales as Store Expansion Bolsters Growth
Jun 10, 2026
TRIAL Holdings reported strong same-store sales in May of its FY6/2026, with same-store sales up 7.2% year-on-year, driven by a 2.0% rise in customer traffic and higher average spending amid favorable weather and additional holidays. Seasonal summ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.